JP Morgan Chase
ARCT icon

JP Morgan Chase’s Arcturus Therapeutics ARCT Stock Holding History

JP Morgan Chase’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-24,000
Closed -$557K – 7382
2024
Q3 		$557K Hold
24,000
– – ﹤0.01% 4829
2024
Q2 		$584K Buy
+24,000
New +$728K ﹤0.01% 4604

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

JP Morgan Chase's ARCT Position: Q2 2026 in Review

JP Morgan Chase reduced its Arcturus Therapeutics (ARCT) stake by 1.1% in Q2 2026, selling an estimated $16.6K and leaving 195,704 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #4479.

JP Morgan Chase first reported a position in ARCT in Q2 2013 and has held it in 40 quarters since. The position peaked at $14.7M in Q1 2014. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • JP Morgan Chase held 195,704 shares of Arcturus Therapeutics worth $1.33M as of Q2 2026.
  • JP Morgan Chase sold 2,111 Arcturus Therapeutics shares in Q2 2026, an estimated $16.6K.
  • Arcturus Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4479 holding.
  • JP Morgan Chase first reported a position in Arcturus Therapeutics in Q2 2013 and has held it in 40 quarters since.
  • JP Morgan Chase's Arcturus Therapeutics position peaked at $14.7M in Q1 2014.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.